Gemcitabine + Adriamycine + Paclitaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Mar 1, 2003 → Jan 1, 2015
NCT ID
NCT00128856About Gemcitabine + Adriamycine + Paclitaxel
Gemcitabine + Adriamycine + Paclitaxel is a phase 2 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00128856. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00128856 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer